Evidence map›Paper›PMID 41800243›Full record

ReviewInternational journal of biological sciences2026

The Yin-Yang balance of SIRT1 and SIRT2 in cancer metabolic remodeling.

Fei Yi, Li Shen, Xindi Yang, Zhuo Wang, Xue Li, Zishi Shen, Wenting Liu, Qi Miao, Shuang Jiang, Eryan Kong and 4 more

Abstract readReview
In one paragraph

Review in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fei YiHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Li ShenHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Xindi YangHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Zhuo WangHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Xue LiHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Zishi ShenHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Wenting LiuHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Qi MiaoInnovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
Shuang JiangInnovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
Eryan KongInstitute of Psychiatry and Neuroscience, Henan Medical University, Xinxiang, Henan 453003, China.
Xiaoyu SongHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Tingting ZhouHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Ning BaiHealth Sciences Institute, China Medical University, Shenyang, Liaoning 110122, China.
Liu CaoInnovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Jinzhou Medical University, Jinzhou, Liaoning 121001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sirtuin 1 (SIRT1) and Sirtuin 2 (SIRT2) are NAD⁺-dependent deacetylases that regulate cancer metabolic stress, exerting their effects primarily through post-translational modification of metabolic enzymes and transcription factors. They modulate glucose, lipid, and mitochondrial metabolism, as well as immune metabolism responses within the tumor microenvironment. Depending on cellular context, they can promote or suppress tumor growth by directing energy production, redox balance, and metabolic adaptation. These context-dependent and often opposing activities constitute a Yin-Yang mode of regulation in cancer metabolism, reflecting a dynamic balance between metabolic activation and constraint. Autophagy has emerged as a critical metabolic integration node regulated by both SIRT1 and SIRT2, linking nutrient sensing, mitochondrial quality control, and stress adaptation. This review summarizes recent advances in understanding how SIRT1 and SIRT2 coordinate tumor metabolism and discusses therapeutic strategies that target their regulatory balance to reprogram cancer metabolism. SIRT2 also functions as a metabolic checkpoint that restrains CD8⁺ T cell effector metabolism, providing a rationale for combining SIRT2 inhibition with immune checkpoint blockade in metabolically stressed tumor microenvironments.

Indexed as

NeoplasmsSirtuin 1Sirtuin 2AnimalsHumansMetabolic ReprogrammingTumor MicroenvironmentSirtuin 1Sirtuin 2glucose metabolismlipid metabolismmitochondrial metabolismSIRT1 and SIRT2tumor immune microenvironment

Identifiers

PMID41800243
PMCPMC12965217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.